Filtered By:
Condition: Heart Valve Disease
Education: Academia
This page shows you your search results in order of date.
Order by Relevance | Date
Total 37 results found since Jan 2013.
Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG Study
CONCLUSIONS: The PORTICO NG Study demonstrates low rates of adverse events and PVL up to 1 year in patients at high or extreme surgical risk, confirming the safety and efficacy of the Navitor THV system.PMID:36895190 | DOI:10.4244/EIJ-D-22-01108
Source: EuroIntervention - March 10, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Lars Sondergaard Antony S Walton Stephen G Worthley Dave Smith Bassem Chehab Ganesh Manoharan Gerald Yong Francesco Bedogni Nicholas Bates Michael J Reardon Source Type: research
Nationwide experience with transcarotid transcatheter aortic valve implantation: Insights from the POL-CAROTID registry
CONCLUSIONS:: The results of the study indicated that the first cohort of transcarotid transcatheter heart valves of second-generation implantations in Poland were associated with a similar prognosis to TF-TAVI with regard to safety and feasibility. TC access may be considered an optimal alternative for patients, in whom the TF approach is precluded.PMID:36594529 | DOI:10.33963/KP.a2022.0288
Source: Kardiologia Polska - January 3, 2023 Category: Cardiology Authors: Radoslaw Wilimski Zenon Huczek Kajetan Grodecki Janusz Kochman Bartosz Rymuza Wojciech Wojakowski Damian Hudziak Dariusz Jagielak Jerzy Sacha Marek Grygier Andrzej Walczak Piotr Hendzel Romuald Cicho ń Marcin Grabowski Mariusz Ku śmierczyk Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study
CONCLUSIONS: Dual antithrombotic therapy is associated with a substantially lower risk of clinically relevant bleeding without a statistically significant penalty in ischaemic events.PMID:35370126 | DOI:10.4244/EIJ-D-21-00703
Source: EuroIntervention - April 4, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Willem Lambertus Bor Anne Johanna Wilhelmina de Veer Renske H Olie Sem A O F Rikken Dean R P P Chan Pin Yin Jean Paul R Herrman Mathias Vrolix Martijn Meuwissen Tom Vandendriessche Carlos van Mieghem Michael Magro Naoual Bennaghmouch Rick Hermanides Tom A Source Type: research
Is oral anticoagulation effective in preventing transcatheter aortic valve implantation failure? A propensity matched analysis of the Italian Transcatheter balloon-Expandable valve Registry study
Conclusion
After TAVI with Edwards Sapien valve OAT did not reduce the incidence of valve dysfunction and stroke but was responsible for mortality and bleeding increases.
Source: Journal of Cardiovascular Medicine - December 27, 2019 Category: Cardiology Tags: Research articles: Interventional cardiology Source Type: research
Impact of Severity of Chronic Kidney Disease on Management and Outcomes Following Transcatheter Aortic Valve Replacement With Newer-Generation Transcatheter Valves.
CONCLUSIONS: In this prospective study of adults undergoing TAVR with newer-generation THVs, moderate and severe CKD was associated with a nearly 2-fold and 3-fold higher risk of 30-day readmission, respectively.
PMID: 31841995 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - December 18, 2019 Category: Cardiology Tags: J Invasive Cardiol Source Type: research
